ProCE Banner Activity

Sequencing Novel SERDs in the Treatment of Patients With HR+/HER2- Metastatic Breast Cancer

Slideset

Download these slides from a live satellite symposium at the San Antonio Breast Cancer Symposium covering strategies for sequencing oral SERDs while managing patients with recurrent HR-positive/HER2-negative metastatic breast cancer.

Released: November 15, 2024

Expiration: November 14, 2025

Share

Faculty

Erica L. Mayer

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly

AstraZeneca

Lilly